ReviewMolecular diversity2025
Application of 18β-glycyrrhetinic acid in the structural modification of natural products: a review.
Review in Molecular diversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Application of 18Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Mechanistic insights into 18β-glycyrrhetinic acid-induced apoptosis in SCC-9 cells revealed by TMT proteomics and network pharmacology.Scientific reports · 2026Article
- Novel Glycyrrhizinic Acid Derivative YCY-20 Inhibits Cerebral Ischemia/Reperfusion Induced Apoptosis via the AGE-RAGE/MAPK Pathway.CNS neuroscience & therapeutics · 2026Article
- Interdisciplinarity traditional Chinese medicine microneedles in skin disease treatment: Recent advances and challenges.Bioactive materials · 2026Review
- The serum levels of polyunsaturated fatty acids contribute to the antidepressant-like effects of 18β-Glycyrrhetinic acid in mice.Psychopharmacology · 2025Article
- The Effect of Gut Microbiome Perturbation on the Bioavailability of Glycyrrhizic Acid in Rats.Pharmaceutics · 2025Article
- Supplementation of 18β-glycyrrhetinic acid attenuates D-galactose-induced oxidative stress and inflammatory responses in kidneys of weaned piglet.Journal of animal science · 2025Article
- GA-LDV: A Promising Derivative of 18β-Glycyrrhetinic Acid with Enhanced in vitro and in vivo Anti-Cancer Properties.Drug design, development and therapy · 2025Article
- Conjugation of Triterpenic Acids with 3-Aminoquinuclidine Moiety: An Approach to Acetylcholinesterase Mixed or Uncompetitive Type Inhibitors.Molecules (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
18β-Glycyrrhetinic acid (GA) is an oleane-type pentacyclic triterpene saponin obtained from glycyrrhizic acid by removing 2 glucuronic acid groups. GA and its analogues are active substances of glycyrrhiza aicd, with similar structure and important pharmacological effects such as anti-inflammatory, anti-diabetes, anti-tumor and anti-fibrosis. Although GA combined compounds are in the clinical trial stages, its application potential is severely restricted by its low bioavailability, water solubility and membrane permeability. In this article, synthetic methods and structure-activity relationships (SARs) of GA derivatives from 2018 to present are reviewed based on pharmacological activity. It is hoped that this review can provide reference for the future development of potential GA preclinical candidate compounds, and furnish ideas for the development of pentacyclic triterpenoid lead compounds.
Indexed as
Identifiers
38683490What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.